Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis: The ACCESS Randomized Trial | Critical Care Medicine | JAMA | JAMA Network

[Skip to Content] Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our cookie policy | Continue